The Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicenter, open-label, randomized controlled, phase 3 trial

Bisogno G, Jenney M, Bergeron C, Gallego Melcón S, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, De Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL, for the EpSSG. The Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicenter, open-label, randomized controlled, phase 3 trial. Lancet Oncol. 2018. pii: S1470-2045(18)30337-1. DOI: 10.1016/S1470-2045(18)30337-1